Log in to your Inderes Free account to see all free content on this page.

Qlucore

0.39 SEK

-12.56 %

Less than 1K followers

QCORE

First North Stockholm

IT Services

Technology

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-12.56 %

-2.99 %

-21.69 %

-4.41 %

-46.21 %

-77.68 %

-94.78 %

-

-98.60 %

Qlucore develops AI-based software for use in the healthcare sector. The company's precision medicine solutions transform genetic data into decision-making data to create the right treatment for patients. The company's first diagnostic test – for blood cancer in children – has been approved and CE-marked. The company also has tests for lung cancer under development, and is developing the Qlucore Omics Explorer analysis software.

Market cap

16.73M SEK

Turnover

3.9K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

28.5.

2026

Annual report '26

10.9.

2026

General meeting '26

All

Press releases

3rd party

ShowingAll content types

Regulatory press release2/26/2026, 7:30 AM

Interim report 1 May 2025 - 31 January 2026

Press release2/23/2026, 4:10 PM

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May 2025 – 31 January 2026

Press release12/18/2025, 1:00 PM

New version of Qlucore Omics Explorer with enhanced support for in-depth proteomics analysis

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/27/2025, 7:30 AM

Interim report 1 May - 31 October 2025

Regulatory press release11/27/2025, 7:20 AM

Disposal of intangible assets

Press release11/25/2025, 10:00 AM

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May – 31 October 2025

Regulatory press release10/28/2025, 8:30 AM

Qlucore terminates liquidity guarantee agreement

Regulatory press release10/23/2025, 10:30 AM

Bulletin from the annual general meeting of Qlucore AB (publ)

Regulatory press release9/24/2025, 4:30 PM

Interim report 1 May - 31 July 2025

Press release9/24/2025, 8:00 AM

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May – 31 July 2025

Regulatory press release9/23/2025, 3:30 PM

NOTICE OF ANNUAL GENERAL MEETING OF QLUCORE AB (publ)

Regulatory press release9/8/2025, 7:00 PM

Last day of trading in BTA in Qlucore – conversion of BTA into shares

Regulatory press release9/4/2025, 6:00 PM

Qlucore carries out a directed share issue to guarantors

Regulatory press release9/1/2025, 5:00 PM

Qlucore announces outcome of rights issue

Regulatory press release8/22/2025, 7:00 AM

Qlucore secures guarantee commitments as well as additional subscription commitments ahead of rights issue

Press release8/14/2025, 9:00 AM

Mubadala Health Dubai Invests in Precision Diagnostics with Qlucore Insights for Lung Cancer and Pediatric Leukemia

Regulatory press release8/7/2025, 3:15 PM

Qlucore publishes information memorandum regarding upcoming rights issue

Regulatory press release7/31/2025, 1:00 PM

Bulletin from the extraordinary general meeting of Qlucore AB (publ)

Regulatory press release7/30/2025, 9:45 AM

Qlucore secures guarantee commitments as well as additional subscription commitments ahead of rights issue

Press release7/22/2025, 1:00 PM

Qlucore expands sales network with New Agent in China

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.